Myocet®, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in adult women.1
Myocet® is a powder, dispersion and solvent for concentrate for dispersion for infusion.
Myocet® is supplied as a three-vial system:
Marketing Authorisation Number(s)
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.